OPKO HEALTH, INC.
Close on Oct 19, 2026
- Market cap
- $1.22B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 27, 2026 | After market close | $163.50M | $-0.01 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 28, 2026 | After market close | $124.20M | $-0.07 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | After market close | $148.50M | $-0.04 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 29, 2025 | After market close | $151.70M | $0.03 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 31, 2025 | After market close | $156.80M | $-0.19 | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 30, 2025 | After market close | $149.90M | $-0.10 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 27, 2025 | After market close | $183.60M | $0.01 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $173.60M | $0.03 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Jul 27, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Total costs and expenses | For the year ended December 31, 2026 | $710.00M to $740.00M | Raised |
| Total costs and expenses | For the three months ended September 30, 2026 | $180.00M to $190.00M | New |
| R&D included in costs and expenses | For the three months ended September 30, 2026 | $34.00M to $38.00M | Lowered |
| R&D included in costs and expenses | For the year ended December 31, 2026 | $125.00M to $135.00M | Lowered |
| Services revenue | For the year ended December 31, 2026 | $296.00M to $306.00M | Raised |
| Product revenue | For the year ended December 31, 2026 | $164.00M to $174.00M | Lowered |
| IP and other revenue | For the year ended December 31, 2026 | $100.00M to $105.00M | Lowered |
| Total revenue | For the year ended December 31, 2026 | $560.00M to $585.00M | Raised |
| Pfizer gross profit share | For the year ended December 31, 2026 | $34.00M to $37.00M | Lowered |
| Services revenue | For the three months ended September 30, 2026 | $73.00M to $78.00M | New |
| Product revenue | For the three months ended September 30, 2026 | $40.00M to $44.00M | Lowered |
| IP and other revenue | For the three months ended September 30, 2026 | $16.00M to $20.00M | Lowered |
| Total revenue | For the three months ended September 30, 2026 | $131.00M to $142.00M | Raised |
| Pfizer gross profit share | For the three months ended September 30, 2026 | $8.00M to $10.00M | Lowered |
| BARDA | For the three months ended September 30, 2026 | $5.00M to $7.00M | Lowered |
| BARDA | For the year ended December 31, 2026 | $18.00M to $22.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Opko Health filed with the SEC
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
Yvonne Briggs, Alliance Advisors IR (investors) - 310-691-7100
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
OPKO Health Reports Fourth Quarter 2024 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
OPKO Health Reports Third Quarter 2024 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
Christin O ’ Donnell (investors) – 336-436-5076
Agreement terminated · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
SUMMARY OF UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS
Agreement terminated · Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLA ’ s Profit Share Payments
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K/A
Regulation FD disclosure · EX-99.1 to Form 8-K/A
EX-99.1 to Form 8-K
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats
Regulation FD disclosure · EX-99.1 to Form 8-K
OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K
OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results
Results of operations · EX-99.1 to Form 8-K